Aprea Therapeutics (APRE) Accounts Payables (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Accounts Payables of $2.9 million for Q1 2026, up 129.45% year-over-year from $1.3 million in Q1 2025, and up 312.06% quarter-over-quarter from $713668.0 in Q4 2025.
Aprea Therapeutics (APRE) Accounts Payables (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Accounts Payables for 9 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 129.45% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 129.45% YoY), while the FY2025 annual figure was $713668.0, down 47.22% from the prior year.
- Accounts Payables rose to $2.9 million in Q1 2026 per APRE's latest filing, from $713668.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $4.0 million in Q2 2022 and bottomed at $641322.0 in Q3 2025.
- Historically, Accounts Payables has averaged $1.4 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 71.65% — and 2026, when it soared 129.45%.
- Aprea Therapeutics' Accounts Payables stood at $842754.0 in 2022, then jumped by 98.2% to $1.7 million in 2023, then retreated by 19.05% to $1.4 million in 2024, then plunged by 47.22% to $713668.0 in 2025, then surged by 312.06% to $2.9 million in 2026.
- Business Quant data shows APRE's Accounts Payables at $2.9 million in Q1 2026, $713668.0 in Q4 2025, and $641322.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | 935,139.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 935,139.00 |
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 713,668.00 |
| Sep 30, 2025 | 641,322.00 |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 964,327.00 |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 862,552.00 |
| Jun 30, 2023 | 1.13 Mn |
| Mar 31, 2023 | 826,027.00 |
| Dec 31, 2022 | 842,754.00 |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 3.99 Mn |
| Mar 31, 2022 | 1.99 Mn |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | 2.55 Mn |